DFCM
MRSN

Dark Forest Capital Management’s Mersana Therapeutics MRSN Stock Holding History

Dark Forest Capital Management’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-12
Closed -$1K – 1328
2022
Q2 		$1K Buy
+12
New +$1.13K ﹤0.01% 804
2022
Q1 		– Sell
-297
Closed -$46K – 1584
2021
Q4 		$46K Buy
+297
New +$57.8K 0.02% 471
2021
Q3 		– Sell
-24
Closed -$8K – 1443
2021
Q2 		$8K Buy
+24
New +$9.09K ﹤0.01% 657

Other funds holding MRSN

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Dark Forest Capital Management's MRSN Position: Q3 2022 in Review

Dark Forest Capital Management sold out of Mersana Therapeutics (MRSN) in Q3 2022, closing a stake of 12 shares — an estimated $1K sold.

Dark Forest Capital Management first reported a position in MRSN in Q2 2021 and held it in 3 quarters. The position peaked at $46K in Q4 2021. 152 funds tracked by Wall St. Rank hold MRSN as of Q3 2022.

  • Dark Forest Capital Management reported no remaining Mersana Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Dark Forest Capital Management sold 12 Mersana Therapeutics shares in Q3 2022, an estimated $1K.
  • Dark Forest Capital Management first reported a position in Mersana Therapeutics in Q2 2021 and held it in 3 quarters.
  • Dark Forest Capital Management's Mersana Therapeutics position peaked at $46K in Q4 2021.
  • 152 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q3 2022.

Based on Dark Forest Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.